Pacira Pharmaceuticals, which is developing a non-opioid postsurgical analgesic pending FDA approval, will see its quiet period end on Monday, March 14. On February 2, the company raised $42 million by offering 6 million shares at $7, below the original range of $14 to $16. Barclays Capital and Piper Jaffray acted as lead managers on the deal.
